Please login to the form below

Not currently logged in
Email:
Password:

Former Genzyme group vice president joins Vedanta Biosciences

Dr Bruce Roberts takes up the role of chief scientific officer

Vedanta Biosciences Dr Bruce RobertsVedanta Biosciences has appointed Dr Bruce Roberts as chief scientific officer at its new Cambridge, Massachusetts, site.

Dr Roberts will take responsibility for the company's research and development division, bringing over 30 years of experience in biotechnology and pharmaceutical drug discovery and development to the firm.

He first joined Sanofi Genzyme as general manager of its Cambridge, UK-based therapeutic antibody centre in 2004 before being promoted to group vice president and head of neuro-immunology and immune-mediated disease research in 2006.

In this role, Dr Roberts directed multiple clinical trials for the treatment of autoimmunity, cancer and multiple sclerosis as well as managing research efforts into a number of now-approved products.

Vedanta's chief executive officer Dr Bernat Olle said: “Bruce brings decades of drug development experience across a broad range of novel biologic drug modalities and a proven track record of driving the discovery and development of multiple approved drugs in immunology.

“His experience and leadership in pioneering new drug modalities will be invaluable as we advance our pipeline of microbiome-modulating therapies.”

Dr Roberts said: “Microbiome modulation is among the most exciting and rapidly evolving fields in science and it has tremendous potential to change the way medicine is practiced.

“I am excited to join one of the leading teams in this field and I look forward to driving Vedanta's technology platform and pipeline forward.”

29th March 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics